Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Radiomics in cardiology

Published byJuniper Turner Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 Radiomics in cardiology"— Presentation transcript:

1 Figure 2 Radiomics in cardiology
Figure 2 | Radiomics in cardiology. The current gold standard for quantification of coronary calcifications visible on CT is the ‘Agatston' method (based upon intensity and volume). Radiomic features can improve quantification, differentiation between calcified and non-calcified plaques, and thus the prediction of Major Adverse Cardiac Events (MACE). Lambin, P. et al. (2017) Radiomics: the bridge between medical imaging and personalized medicine Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 2 Radiomics in cardiology"

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,
Figure 1 Estimated annual percentages of new

Figure 1 Estimated annual percentages of new
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 3 Response after appearance of a new lesion

Figure 3 Response after appearance of a new lesion
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 New functional imaging techniques in lymphoma

Figure 2 New functional imaging techniques in lymphoma
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Three-step approach to the assessment and management

Figure 2 Three-step approach to the assessment and management
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma
Figure 5 Identification of mucinous carcinoma

Figure 5 Identification of mucinous carcinoma
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Similar presentations

Ads by Google